ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells

FEBS Letters

Volumn 586, Issue 24, 2012, Pages 4311-4318

  Dhyani, Anamika ^a   Duarte, Adriana S S ^a   MacHado Neto, João A ^a   Favaro, Patricia ^a,b   Ortega, Manoela Marques ^a   Olalla Saad, Sara T ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ANKHD1; Cell cycle; Multiple myeloma; p21; Proliferation

Indexed keywords

ANKHD1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLUCOCORTICOID; PROTEIN P53; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; MM CELL LINE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; S PHASE CELL CYCLE CHECKPOINT; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE SILENCING; GLUCOCORTICOIDS; HUMANS; MULTIPLE MYELOMA; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84870526209     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.10.037     Document Type: Article

References (31)

1. L. Lopez-Corral, N.C. Gutierrez, M.B. Vidriales, M.V. Mateos, A. Rasillo, R. Garcia-Sanz, B. Paiva, and J.F. San Miguel The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells Clin. Cancer Res. 17 2011 1692 1700
2. A. Palumbo, and K. Anderson Multiple myeloma N. Engl. J. Med. 364 2011 1046 1060
3. M.S. Raab, K. Podar, I. Breitkreutz, P.G. Richardson, and K.C. Anderson Multiple myeloma Lancet 374 2009 324 339
4. P.L. Bergsagel, and W.M. Kuehl Chromosome translocations in multiple myeloma Oncogene 20 2001 5611 5622
5. P. Joy Ho Chromosomal and genetic abnormalities in myeloma Clin. Lab. Haematol. 24 2002 259 269
6. F. Merchionne, F. Perosa, and F. Dammacco New therapies in multiple myeloma Clin. Exp. Med. 7 2007 83 97
7. S.K. Kumar Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2008 2516 2520
8. J.A. Child High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N. Engl. J. Med. 348 2003 1875 1883
9. M. Mesri, N.R. Wall, J. Li, R.W. Kim, and D.C. Altieri Cancer gene therapy using a surviving mutant adenovirus J. Clin. Invest. 108 2001 981 990
10. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 2003 721 732
11. G.F. Weber The metastasis gene osteopontin: a candidate target for cancer therapy Biochim. Biophys. Acta 1552 2001 61 85
12. L. Chen, Q. Liu, R. Qin, H. Le, R. Xia, W. Li, and M. Kumar Amplification and functional characterization of MUC1 promoter and gene-virotherapy via a targeting adenoviral vector expressing hSSTR2 gene in MUC1-positive Panc-1 pancreatic cancer cells in vitro Int. J. Mol. Med. 15 2005 617 626
13. J.S. Boehm, and W.C. Hahn Towards systematic functional characterization of cancer genomes Nat. Rev. Genet. 12 2011 487 498
14. F. Traina, P.M. Favaro, S. Medina Sde, S. Duarte Ada, S.M. Winnischofer, F.F. Costa, and S.T. Saad ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells Biochim. Biophys. Acta 1762 2006 828 834
15. J.A. Machado-Neto, P. Favaro, M. Lazarini, F.F. Costa, S.T. Olalla Saad, and F. Traina Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells Biochim. Biophys. Acta 1813 2011 1404 1411
16. M.A. Rizvi, K. Ghias, K.M. Davies, C. Ma, F. Weinberg, H.G. Munshi, N.L. Krett, and S.T. Rosen Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines Mol. Cancer Ther. 5 2006 1783 1789
17. D. Stiller, and D. Katenkamp Intercellular substances in Hodgkin's lymphomas. Ultrastructural investigations Virchows Arch. A Pathol. Anat. Histol. 380 1978 81 90
18. S. Belanger, M. Cote, D. Lane, S. L'Esperance, C. Rancourt, and A. Piche Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells Gynecol. Oncol. 97 2005 796 806
19. C. Haferlach, U. Bacher, A. Kohlmann, S. Schindela, T. Alpermann, W. Kern, S. Schnittger, and T. Haferlach CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia Haematologica 96 2011 829 836
20. S. Molatore, E. Kiermaier, C.B. Jung, M. Lee, E. Pulz, H. Hofler, M.J. Atkinson, and N.S. Pellegata Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors Mol. Cancer Ther. 9 2010 116
21. J. Liu, J.L. Hu, B.W. Shi, Y. He, and W.X. Hu Up-regulation of p21 and TNF-alpha is mediated in lycorine-induced death of HL-60 cells Cancer Cell Int. 10 2010 25
22. P.L. Kuo, W.C. Ni, E.M. Tsai, and Y.L. Hsu Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells Mol. Cancer Ther. 8 2009 1328 1339
23. V. Gottifredi, K. McKinney, M.V. Poyurovsky, and C. Prives Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block J. Biol. Chem. 279 2004 5802 5810
24. D.G. Johnson, and C.L. Walker Cyclins and cell cycle checkpoints Annu. Rev. Pharmacol. Toxicol. 39 1999 295 312
25. R.A. Woo, and R.Y. Poon Cyclin-dependent kinases and S phase control in mammalian cells Cell Cycle 2 2003 316 324
26. A. Peiretti, N. Baghdassarian, L.M. Gerland, P. Ffrench, P.A. Bryon, J.P. Magaud, and M. Ffrench CDK2 is involved in the S-phase lengthening induced by glucocorticoids in normal human lymphocytes Eur. J. Cell Biol. 82 2003 253 261
27. Y. Zhu, C. Alvarez, R. Doll, H. Kurata, X.M. Schebye, D. Parry, and E. Lees Intra-S-phase checkpoint activation by direct CDK2 inhibition Mol. Cell. Biol. 24 2004 6268 6277
28. M.N. Saha, H. Jiang, A. Mukai, and H. Chang RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses Mol. Cancer Ther. 9 2010 3041 3051
29. X. Yang, W. Wang, J.J. Qin, M.H. Wang, H. Sharma, J.K. Buolamwini, H. Wang, and R. Zhang JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21 PLoS One 7 2012 e34303
30. N. Takagaki, Y. Sowa, T. Oki, R. Nakanishi, S. Yogosawa, and T. Sakai Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway Int. J. Oncol. 26 2005 185 189
31. K. Lin, N. Rockliffe, G.G. Johnson, P.D. Sherrington, and A.R. Pettitt Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells Oncogene 27 2008 2445 2455